Universidad de Investigación para la Generación y Síntesis de Evidencia en Salud, Universidad San Ignacio de Loyola
2 ARTICLES PUBLISHED IN JoVE
Neuroscience
Measuring Contralateral Silent Period Induced by Single-Pulse Transcranial Magnetic Stimulation to Investigate M1 Corticospinal Inhibition
Ingrid Rebello-Sanchez 1, Joao Parente 1, Kevin Pacheco-Barrios 1,2, Anna Marduy 1, Danielle Carolina Pimenta 1, Daniel Lima 1, Eric Slawka 1, Alejandra Cardenas-Rojas 1, Gleysson Rodrigues Rosa 1, Kamran Nazim 3, Abhishek Datta 3,4, Felipe Fregni 1
1Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, 2Universidad de Investigación para la Generación y Síntesis de Evidencia en Salud, Universidad San Ignacio de Loyola, 3Research and Development, Soterix Medical, 4City College of New York
Contralateral silent period (cSP) assessment is a promising biomarker to index cortical excitability and treatment response. We demonstrate a protocol to assess cSP intended for studying M1 corticospinal inhibition of upper and lower limbs.
Neuroscience
Understanding the Effects of Non-Invasive Transauricular Vagus Nerve Stimulation on EEG and HRV
Anna Carolyna Gianlorenco 1,2, Kevin Pacheco-Barrios 1,3, Lucas Camargo 1, Elly Pichardo 1, Hyuk Choi 4,5, Jae-Jun Song 5,6, Felipe Fregni 1
1Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, 2Physical Therapy Department, Federal University of Sao Carlos, 3Vicerrectorado de Investigación, Universidad de Investigación para la Generación y Síntesis de Evidencia en Salud, Universidad San Ignacio de Loyola, 4Department of Medical Sciences, Graduate School of Medicine, Korea University, 5Neurive Co., Ltd., 6Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Medical Center
This protocol provides information on how to apply transcutaneous auricular vagus nerve stimulation (taVNS) in a clinical trial, including potential biomarkers such as EEG metrics and heart rate variability (HRV) to measure the effect of this treatment on the autonomic nervous system.
